Ozcan, M. Et Al. 2024. BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).. JOURNAL OF CLINICAL ONCOLOGY , no.16 .

Ozcan, M., Lavie, D., Chaudhry, A., Zhou, X., Paydar, I., Farooqui, M. Z. H., ... Ghia, P.(2024). BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).. JOURNAL OF CLINICAL ONCOLOGY , no.16.

Ozcan, MUHİT Et Al. "BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).," JOURNAL OF CLINICAL ONCOLOGY , no.16, 2024

Ozcan, MUHİT Et Al. "BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).." JOURNAL OF CLINICAL ONCOLOGY , no.16, 2024

Ozcan, M. Et Al. (2024) . "BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).." JOURNAL OF CLINICAL ONCOLOGY , no.16.

@article{article, author={MUHİT ÖZCAN Et Al. }, title={BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2024}